DEVLIES PHARMA
ActiveSummary
DEVLIES PHARMA has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €149,857 and a net result of -€13,894. Equity remains stable across the filed fiscal years (±0.3% per year). Its solvency ranks better than 33% of 12396 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2025
15-12
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
30-06
Financial
Weakest financial yearnet -€13,894
Net result drops to -€13,894, the lowest in the series.
2024
30-12
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
30-06
Financial
Highest result since 2019net €5,533 ▲744%
Operating result €27,838, net result €5,533, both a record.
2023
18-12
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2022
30-12
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2021
21-12
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2020
31-12
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2019
16-12
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
24-01
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
31-01
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2016
26-12
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 6 acts read
About the unread acts
We know of 6 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.